At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
fCO2 Laser Therapy Groupdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fractional Carbon Dioxide Laser Therapy of the Vagina for Treatment of Urogenital Symptoms in Women
In Brief
An observational study evaluating fCO2 Laser Therapy Group for Genitourinary System; Disorder, Female and 8 related conditions. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This is a prospective observational study of women undergoing vaginal treatment with the fractional carbon dioxide (fCO2) laser for various urogenital symptoms.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGenitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionDec 2022
Study CompletionJun 2025
TodayJul 2026
First PostedSep 24, 2018
Enrollment StartOct 8, 2018
Primary CompletionDec 15, 2022
Study CompletionJun 10, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.8 years ago
Interventions
fCO2 Laser Therapy Groupdevice
Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.